What to do when a medication has no PBS listing for the claimed condition
Navigating off-label prescriptions and unlisted indications in insurance claims
Published: 3 April 2026 | Updated: 3 April 2026
Why this matters to you
You've received a claim for medication that works for your claimant's condition, but it has no Pharmaceutical Benefits Scheme listing for that indication. This scenario sits at the intersection of clinical efficacy and reimbursement policy. Your responsibility is to determine whether funding is justified, whether the prescriber's rationale holds water, and whether this medication represents the right choice for this claimant at this time.
Off-label use is common in legitimate clinical practice. The question isn't whether it happens; it's whether you should pay for it.
The key distinction: unlisted use vs. off-label use
These terms are often used interchangeably, but they're slightly different:
- Unlisted use: The medication is on the PBS, but only for specific conditions. Your claimant's condition isn't on that list.
- Off-label use: The prescriber is using an approved medication outside the terms of its registered product information, even if it has PBS coverage for other indications.
Both scenarios require you to ask: Is there sufficient clinical evidence to justify funding this prescription?
Your starting point: Off-label and unlisted prescriptions aren't automatically unreasonable. Good prescribers use them when evidence supports better outcomes. Your role is to verify that evidence exists and that this use is appropriate for this claimant's clinical context.
Assessment framework: five questions to ask
When you receive a claim for a medication with no PBS listing for the claimed condition, work through these questions systematically:
1. Is there peer-reviewed evidence for this use?
Request the prescriber provide the clinical evidence supporting this choice. This might be published research, clinical guidelines, or established off-label practice standards. If they can't cite evidence, that's your first red flag. Legitimate off-label use has a clinical paper trail.
2. Have standard listed options been exhausted or ruled out?
If a PBS-listed medication exists for this condition, why hasn't it been used? The prescriber should clearly articulate why the claimant either can't tolerate listed options, hasn't responded to them, or has contraindications. This demonstrates they've thought through alternatives.
3. Is there documented prescriber specialisation in this area?
A psychiatrist using an off-label antipsychotic for anxiety carries different weight than a GP using it for an unrelated condition. Specialist prescribers generally have deeper knowledge of off-label evidence bases. Check whether the prescriber operates within their area of recognized expertise.
4. Are there safety or efficacy concerns specific to this claimant?
Some off-label uses are well-established (fluoxetine for fibromyalgia). Others are experimental or carry higher risk profiles. Review the claimant's medical history, comorbidities, and medication interactions. What's reasonable for one claimant may be risky for another.
5. Is the dosing and duration appropriate?
Even if the use is justified, is the prescriber dosing it correctly for this indication? Some off-label uses require different doses than the PBS listing. Check whether the prescription aligns with evidence-based dosing for this specific use.
Common scenarios and how to handle them
Scenario A: Established off-label use with strong evidence base
Example: tricyclic antidepressants for neuropathic pain, when the claimant hasn't tolerated gabapentin. This use has substantial clinical trial support and is recommended in pain management guidelines. The prescriber is a pain specialist. Dosing is within the evidence-based range.
Your call: Refer for a pharmacy review. The evidence is solid, alternatives have been trialled, and the prescriber has specialist credentials. This is defensible funding.
Scenario B: Novel or poorly evidenced use
Example: a medication approved only for hypertension, prescribed off-label for a psychiatric condition, with minimal published evidence. The prescriber can't cite clinical guidelines supporting this use. No documented trial of standard listed alternatives.
Your call: Request a detailed clinical justification from the prescriber. Ask them to cite the evidence base and explain why listed options aren't suitable. If they can't provide it, consider declining or requesting an independent medication review. This is where specialist pharmacy input becomes valuable.
Scenario C: High-dose or prolonged off-label use
Example: a medication with evidence for short-term off-label use, but the claimant has been on it for 18 months at escalating doses. The evidence base may support 8-12 weeks, not indefinite use.
Your call: This warrants a medication review. Off-label use justifiable for a defined trial period may not be justifiable for long-term continuation. A pharmacist can assess whether the claimant is getting benefit and whether deprescribing or switching to a listed alternative should be considered.
Documentation you should request
Before making a funding decision, request the prescriber provide:
- Clinical notes explaining why this medication was chosen and why standard listed options aren't suitable
- A reference to published evidence, clinical guidelines, or established off-label practice supporting this use
- Evidence of documented trials of alternative medications, if applicable
- Any specialist opinion or consultation notes relevant to this prescription
- The intended duration of this off-label use (trial period vs. long-term continuation)
- How the claimant's response will be monitored and reviewed
When to refer for a pharmacy review
You don't need to be a pharmacist to make funding decisions about off-label medications, but you do need good information. A medication review is particularly useful when:
- The evidence base is complex or you're not confident in your assessment
- Multiple off-label medications are being used simultaneously
- The claimant has comorbidities or other medications that create interaction risks
- You want ongoing monitoring to determine whether to continue funding a trial of off-label therapy
- The prescriber can't articulate a clear clinical justification
| Scenario | Red Flag? | Suggested Action |
|---|---|---|
| Off-label use with published RCT support; specialist prescriber | No | Refer for pharmacy review; likely approvable |
| Off-label use with minimal evidence; GP prescriber; no documented alternative trials | Yes | Request prescriber justification; consider declining pending evidence |
| Off-label use approved for short-term, but claimant is 12 months in | Moderate | Refer for review; assess deprescribing or switching options |
| Multiple off-label medications with potential interactions | Yes | Mandatory medication review to assess safety and rationale |
What you need to know about PBS reimbursement policy
Here's the practical reality: the PBS listing defines what the system will normally fund. If a medication isn't listed for a condition, the pharmacist can dispense it (they're not breaking any law), but you're under no obligation to fund it. This is where you have discretion.
That discretion isn't a blank cheque to refuse anything unlisted. It's a responsibility to evaluate whether exceptional circumstances justify funding outside the normal scheme. Those circumstances generally involve: strong clinical evidence, specialist input, documented alternatives exhausted, and clear monitoring plans.
Medicare and private insurers handle this differently: Medicare typically won't cover unlisted medications. Your scheme (workers compensation, CTP, life insurance, NDIS) may have different policies. Know your scheme's position on off-label funding before you make decisions. This should be documented in your medication funding guidelines.
Key takeaways
- Off-label use isn't automatically unreasonable; it requires scrutiny, not automatic denial
- Request documentation of the clinical evidence and prescriber rationale
- Verify that standard listed options have been considered or trialled first
- Use the five-question framework to structure your assessment
- Refer for a pharmacy review when the clinical case is complex or evidence is unclear
- Document your decision and the reasoning behind it for audit and consistency
Uncertain about an off-label prescription?
IMM specializes in unpacking medication decisions that sit in grey zones. Our pharmacists review complex prescriptions, advise on PBS policy alignment, and help you make defensible funding decisions. We work with insurers to translate clinical evidence into practical claim decisions.
Request a Medication Review
